Effect of a single bolus of methylene blue prophylaxis on vasopressor and transfusion requirement in infective endocarditis patients undergoing cardiac surgery

被引:15
作者
Cho, Jin Sun [1 ]
Song, Jong Wook [1 ,2 ]
Na, Sungwon [1 ,2 ]
Moon, Joo-Hwa [1 ]
Kwak, Young Lan [1 ,2 ,3 ]
机构
[1] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Seoul, South Korea
[3] Yonsei Univ, Coll Med, Severance Biomed Sci Inst, Seoul, South Korea
关键词
Cardiopulmonary bypass; Infective endocarditis; Methylene blue; Vasoplegia;
D O I
10.4097/kjae.2012.63.2.142
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: The accentuated nitric oxide (NO) release that is induced by the systemic inflammatory response associated with infective endocarditis (IE) and cardiopulmonary bypass (CPB) may result in catecholamine refractory hypotension (vasoplegia) and increased transfusion requirement due to platelet inhibition. Methylene blue (MB) is an inhibitory drug of inducible NO. We aimed to evaluate the effect of prophylactic MB administration before CPB on vasopressor and transfusion requirements in patients with IE undergoing valvular heart surgery (VHS). Methods: Forty-two adult patients were randomly assigned to receive 2 mg/kg of MB (MB group, n = 21) or saline (control group, n = 21) for 20 min before the initiation of CPB. The primary end points were comparisons of vasopressor requirements serially assessed after weaning from CPB and hemodynamic parameters serially recorded before and after CPB. The secondary endpoint was the comparison of transfusion requirements. Results: Two patients in the control group received MB after weaning from CPB due to norepinephrine and vasopressin refractory vasoplegia and were thus excluded. There were no significant differences in vasopressor requirements and hemodynamic parameters between the two groups. The mean number of units of packed erythrocytes transfused per transfused patient was significantly less in the MB group. The numbers of patients transfused with fresh frozen plasma and platelet concentrates were less in the MB group. Conclusions: In IE patients undergoing VHS, prophylactic MB administration before CPB did not confer significant benefits in terms of vasopressor requirements and hemodynamic parameters, but it was associated with a significant reduction in transfusion requirement.
引用
收藏
页码:142 / 148
页数:7
相关论文
共 26 条
  • [1] Grayling M., Deakin C.D., Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis, J Thorac Cardiovasc Surg, 125, pp. 426-427, (2003)
  • [2] Beynon R.P., Bahl V.K., Prendergast B.D., Infective endocarditis, BMJ, 333, pp. 334-339, (2006)
  • [3] Smolenski A., Novel roles of cAMP/cGMP dependent signaling in platelets, J Thromb Haemost, 10, pp. 167-176, (2012)
  • [4] Warren O.J., Smith A.J., Alexiou C., Rogers P.L., Jawad N., Vincent C., Et al., The inflammatory response to cardiopulmonary bypass: Part 1--mechanisms of pathogenesis, J Cardiothorac Vasc Anesth, 23, pp. 223-231, (2009)
  • [5] Mekontso-Dessap A., Houel R., Soustelle C., Kirsch M., Thebert D., Loisance D.Y., Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function, Ann Thorac Surg, 71, pp. 1428-1432, (2001)
  • [6] Evora P.R., Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock?, J Thorac Cardiovasc Surg, 119, pp. 632-634, (2000)
  • [7] Levin R.L., Degrange M.A., Bruno G.F., del Mazo C.D., Taborda D.J., Griotti J.J., Et al., Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery, Ann Thorac Surg, 77, pp. 496-499, (2004)
  • [8] Kirov M.Y., Evgenov O.V., Evgenov N.V., Egorina E.M., Sovershaev M.A., Sveinbjornsson B., Et al., Infusion of methylene blue in human septic shock: A pilot, randomized, controlled study, Crit Care Med, 29, pp. 1860-1867, (2001)
  • [9] Daemen-Gubbels C.R., Groeneveld P.H., Groeneveld A.B., van Kamp G.J., Bronsveld W., Thijs L.G., Methylene blue increases myocardial function in septic shock, Crit Care Med, 23, pp. 1363-1370, (1995)
  • [10] Preiser J.C., Lejeune P., Roman A., Carlier E., de Backer D., Leeman M., Et al., Methylene blue administration in septic shock: A clinical trial, Crit Care Med, 23, pp. 259-264, (1995)